Condition: Herpes Zoster · mRNA Vaccine · Sponsor: Sinovac Biotech Co., Ltd
This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.
This description comes directly from the study's public registry record.
Na Xie · 86+1999015105 · xn@xjcdc.com
Jiao Xue · 86+13899089997 · 64282811@qq.com
Always discuss trial participation with your own doctor first.
| Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention | Xinjiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07400003